S-1/A: GRI Bio Amends Wainwright Engagement, Extends Term

GRI Bio, Inc. amended its engagement agreement with H.C. Wainwright & Co., LLC, extending the term for capital raising activities and removing the right of first refusal.

Summary

• GRI Bio, Inc. (the Company) has an exclusive engagement agreement with H.C. Wainwright & Co., LLC (Wainwright) to serve as its underwriter, agent, or advisor for capital-raising offerings of securities.
• The scope of offerings includes warrant restructuring, inducement, exercise solicitation, renegotiating warrant terms, and an at-the-market (ATM) facility.
• Wainwright's compensation includes a cash fee of 7.0% of aggregate gross proceeds for most offerings, reduced to 3.0% for ATM takedowns and 3.5% for proceeds from existing officers/directors (Insiders).
• Wainwright will also receive warrants (Wainwright Warrants) to purchase 7.0% of the aggregate number of shares (or common stock equivalent) placed in each offering (excluding ATM), with a 5-year term and an exercise price of 125% of the offering price.
• Expense allowances include a 1.0% management fee, $25,000 for non-accountable expenses, and up to $50,000 for legal and out-of-pocket expenses (increased to $100,000 for public offerings), plus electronic roadshow costs.
• For ATM offerings, Wainwright will receive up to $100,000 for legal counsel fees in addition to other out-of-pocket expenses.
• A 'tail' provision entitles Wainwright to compensation for any financing within 12 months post-termination if capital is provided by investors Wainwright contacted or introduced during the Term (excluding Insiders and certain private placements).
• The initial term of Wainwright's exclusive engagement began on October 21, 2024, for 90 days, with an extension of an additional 90 days if an offering is consummated within the initial term.
• An amendment dated December 5, 2025, further extends the engagement term by an additional twelve (12) months following its current expiration date, contingent on an offering being consummated after the amendment date.
• The December 5, 2025 amendment also explicitly deletes the 'Right of First Refusal' clause (Paragraph A.5) from the original engagement agreement.

Sentiment

Score: 6

Explanation: The company has secured an exclusive financial advisor for capital raising and extended the engagement term, which is positive for its ability to access funding. However, the compensation structure for the advisor is relatively high, and the exclusivity limits the company's options during the term. The removal of the right of first refusal is a favorable change for the company's long-term flexibility.

Positives

• Secures an exclusive financial advisor (H.C. Wainwright & Co., LLC) for capital raising, providing dedicated support for future offerings.
• The engagement term is extended, providing longer-term advisory services for potential capital raises.
• Removal of the 'Right of First Refusal' grants GRI Bio more flexibility in choosing advisors for future financing rounds beyond the current engagement.

Negatives

• High compensation structure for Wainwright, including a 7.0% cash fee (or underwriter discount) and 7.0% warrant coverage on gross proceeds for most offerings, which could dilute existing shareholders and reduce net proceeds.
• The 'tail' provision means the Company may owe fees to Wainwright for up to 12 months post-termination for investors introduced during the term, limiting future flexibility.
• Exclusivity clause restricts the Company from seeking other advisors or pursuing alternative financing without Wainwright's coordination during the engagement term.

Risks

• Market conditions may prevent a successful offering, as Wainwright's assistance is on a 'reasonable best efforts basis' and does not guarantee success.
• Potential for significant shareholder dilution due to warrant coverage and the issuance of new securities in offerings.
• Financial obligations to Wainwright (fees, expenses, indemnification) could be substantial, regardless of offering success.
• The Company's reliance on Wainwright for capital raising means any issues with Wainwright's performance or market access could hinder financing efforts.

Future Outlook

The company is actively preparing for future capital raising activities, including potential public or private offerings, warrant restructuring, and utilizing an at-the-market facility, with H.C. Wainwright & Co., LLC as its exclusive financial advisor. The extended engagement term suggests a longer-term strategy for securing funding.

Management Comments

• Wainwright shall serve as the exclusive underwriter, agent or advisor in any offering of securities of the Company for the purpose of raising capital to the Company during the Term.
• If an Offering is consummated following the date of this Amendment, the Term of the Engagement Agreement shall be further extended by an additional twelve (12) months following its current expiration date.
• Paragraph A.5 of the Engagement Agreement shall be deleted in its entirety and all references to right of first refusal included in the Engagement Agreement shall be deleted in their entirety.

Industry Context

The engagement of an exclusive placement agent like H.C. Wainwright & Co., LLC, known for its work with small-cap and biotech companies, is a common strategy for emerging growth companies, particularly in the biotechnology sector, to secure necessary capital for research, development, and operations. The terms, including high fees and warrant coverage, are typical for companies seeking funding in a competitive and often high-risk industry where traditional financing might be less accessible. The removal of the right of first refusal could indicate a desire for more flexibility in a dynamic market.

Comparison to Industry Standards

• The 7.0% cash fee and 7.0% warrant coverage for non-ATM offerings are on the higher end of industry standards for small-cap and emerging growth companies, especially in the biotech sector, reflecting the perceived risk and effort involved in raising capital for such entities. For larger, more established companies, fees are typically lower (e.g., 2-5%).
• The 3.0% ATM fee is within the typical range (1-3%) for such facilities.
• The 125% exercise price for warrants is a common premium in these types of engagement agreements.
• The 12-month tail provision is standard in engagement agreements to protect the advisor's efforts.
• The removal of the right of first refusal is a positive for the company, as it provides more flexibility compared to many industry agreements that retain such clauses.

Corporate Governance

Related Party Transactions

• The engagement agreement specifies a lower cash fee (3.5%) for gross proceeds raised from the Company's existing officers and/or directors and their affiliates (Insiders), indicating potential related party involvement in future capital raises.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity offerings and warrants issued to the placement agent. The high fees and warrant coverage will reduce net proceeds from capital raises.
• Company Management: Gains dedicated support for capital raising efforts, but is bound by exclusivity and compensation terms.
• Creditors: May view successful capital raises as positive for the company's financial stability, but dilution could impact equity cushion.

Next Steps

• GRI Bio, Inc. will continue to work with H.C. Wainwright & Co., LLC to identify and execute capital-raising transactions.
• Potential future offerings of securities, including warrant restructuring and ATM takedowns, are contemplated.
• The Company will need to mutually agree on the terms of each offering with Wainwright.

Key Dates

Recommendation

The filing indicates the company is actively pursuing capital raises, which is essential for its operations, especially for a biotech firm. Securing an exclusive advisor and extending the term provides clarity on its financing strategy. However, the high fees and warrant coverage associated with the engagement could lead to significant shareholder dilution. While the removal of the right of first refusal offers some long-term flexibility, the immediate impact of potential dilution and the costs of capital raising warrant a cautious 'hold' stance until more details on specific offerings and their terms become available. Investors should monitor the actual capital raises and their impact on the share structure.

Keywords

GRI Bio, H.C. Wainwright, capital raise, engagement agreement, underwriting, ATM, warrants, financing, SEC filing, S-1/A, biotechnology